Legend Biotech Corporation announced that China's National Medical Products Admi This submission is based on data from the confirmatory Phase 2 clinical study CARTIFAN-1 (NCT03758417) conducted in China, which evaluated the efficacy and safety of cilta-cel in adult patients with relapsed or refractory multiple myeloma who have received 3 or more prior lines of therapy, including a proteasome inhibitor and immunomodulatory drug. nistration (NMPA) has formally accepted its New Drug Application (NDA) for ciltacabtagene autoleucel (cilta-cel).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.91 USD | +2.62% | +2.80% | -23.70% |
04/07 | Genscript Biotech's Phase 3 Multiple Myeloma Drug Trial Yields Positive Results | MT |
02/07 | Legend Biotech Says Myeloma Drug Shows Positive Overall Survival Results | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.70% | 836.86Cr | |
+15.58% | 12TCr | |
+16.60% | 11TCr | |
+17.73% | 2.59TCr | |
-24.33% | 1.93TCr | |
-19.35% | 1.6TCr | |
-17.95% | 1.57TCr | |
-48.32% | 1.49TCr | |
+58.78% | 1.45TCr | |
+4.91% | 1.39TCr |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China